Cover Image
市場調查報告書

OpportunityAnalyzer:頭頸椎扁平表皮癌症 (HNSCC) - 機會分析與預測

OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2024

出版商 GlobalData 商品編碼 357498
出版日期 內容資訊 英文 250 Pages
訂單完成後即時交付
價格
Back to Top
OpportunityAnalyzer:頭頸椎扁平表皮癌症 (HNSCC) - 機會分析與預測 OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2024
出版日期: 2016年02月02日 內容資訊: 英文 250 Pages
簡介

主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本) 的頭頸椎扁平表皮癌症 (HNSCC) 的治療藥市場,預計從2014年的3億8,600萬美元,到2024年擴大到15億3,000萬美元,以14.8%的年複合成長率 (CAGR) 成長。

本報告提供頭頸椎扁平表皮癌症 (HNSCC) 的治療藥市場相關調查分析,疾病概要,流行病學,目前治療選項,未滿足需求和機會,研究開發策略,開發平台評估等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
  • 診斷
  • 症狀
  • 預後

第4章 流行病學

  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 頭頸椎扁平表皮癌症 (HNSCC) 的流行病學預測
    • 確診的患者數
    • 確診的患者數 (各年齡)
    • 確診的患者數 (性別)
    • 確診的患者數 (年齡標準化)等
  • 討論
    • 流行病學預測的考察
    • 分析的限制
    • 分析的優勢

第5章 目前治療選項

  • 概要
  • 產品簡介
  • 標準的化療

第6章 未滿足需求評估與機會分析

  • 概要
  • 未滿足需求分析

第7章 研究開發 (R&D) 策略

  • 概要
  • 臨床試驗設計

第8章 開發平台評估

第9章 開發平台評估分析

  • 主要開發平台藥物臨床基準
  • 主要開發平台藥物的商業基準
  • 競爭評估
  • 銷售額的10年預測
    • 美國
    • EU5個國家
    • 日本

第10章 附錄

圖表

目錄
Product Code: GDHC054POA

The head and neck cancer (HNC) market is one currently dominated by generic chemotherapies, with little competition from branded therapies. The market landscape is set to undergo substantial growth between 2014 and 2024. The main drivers of growth will be an increase in the diagnosed HNC population and the launch of multiple premium-priced metastatic therapies, led by the class of immuno-oncology products. Historically, cytotoxic chemotherapies have comprised the bulk of the HNC market. Little competition between targeted therapies currently exists in the HNC market, leaving an area of considerable opportunity for interested new comers. Cisplatin is the standard treatment for HNC, due to its greater efficacy over other chemotherapy agents. However, as a cytotoxic agent, its use is limited by its high toxicity and poor safety profile.

The recent investment in HNC has seen a significant increase in research activity. The launch of new agents into the market and continued innovation in the developmental pipeline promises to produce a dynamic market over the forecast period.

Highlights

Key Questions Answered

  • The HNC market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the HNC market?
  • The late-stage HNC pipeline is varied and innovative. Will the late-stage drugs make a significant impact on the HNC market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
  • The current HNC market is dominated by generic chemotherapy regimens with little branded competition. How will the advent of new targeted therapies change the treatment landscape for HNC? How will the drug treatment rate change over the next ten years? What are the key drivers and barriers to this change?

Key Findings

  • New drug launches will increase competition and drive expansion of the HNC market. Over the forecast period, six pipeline drugs are expected to file for approval in HNC and the launch of these premium priced agents will drive significant increase in total drug sales in the 7MM.
  • Immuno-oncology agents will be a major driver of treatment innovation. Results from ongoing clinical trials are highly anticipated by the medical community and combination therapies hold promise of greater treatment efficacy.
  • The lack of predictive biomarkers in HNC will continue to pose an issue in adopting personalized treatment, and the increasing costs of new therapies will make this a more pressing issue.
  • KOLs interviewed for this report expressed a need for better treatments in earlier lines of disease in order for treatments to be effective. There needs to be an emphasis on the prevention of disease recurrence, not just treating the recurrences after they occur.

Scope

  • Overview of HNC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized HNC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HNC therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global HNC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global HNC therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HNC therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Track drug sales in the global HNC therapeutics market from 2014-2024.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Biomarkers
    • 3.1.3. Pathophysiology
    • 3.1.4. Clinical Staging
  • 3.2. Diagnosis
  • 3.3. Symptoms
  • 3.4. Prognosis
    • 3.4.1. Quality of Life

4. Epidemiology

  • 4.1. Risk Factors and Comorbidities
  • 4.2. Global and Historical Trends
    • 4.2.1. Incidence
    • 4.2.2. Relative Survival - 7MM
  • 4.3. Forecast Methodology
    • 4.3.1. Sources Used
    • 4.3.2. Sources Not Used
    • 4.3.3. Forecast Assumptions and Methods
  • 4.4. Epidemiological Forecast for HNC and Thyroid Cancer (2014-2024)
    • 4.4.1. Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer
    • 4.4.2. Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers
    • 4.4.3. Diagnosed Incident Cases of Larynx Cancer
    • 4.4.4. Diagnosed Incident Cases of HNC
    • 4.4.5. Diagnosed Incident Cases of Thyroid Cancer
    • 4.4.6. Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer
    • 4.4.7. Age-Specific Diagnosed Incident Cases of Larynx Cancer
    • 4.4.8. Age-Specific Diagnosed Incident Cases of Thyroid Cancer
    • 4.4.9. Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer
    • 4.4.10. Sex-Specific Diagnosed Incident Cases of Larynx Cancer
    • 4.4.11. Sex-Specific Diagnosed Incident Cases of Thyroid Cancer
    • 4.4.12. Age-Standardized Diagnosed Incidence of Lip, Oral Cavity, and Pharynx Cancer
    • 4.4.13. Age-Standardized Diagnosed Incidence of Larynx Cancer
    • 4.4.14. Age-Standardized Diagnosed Incidence of Thyroid Cancer
    • 4.4.15. Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Clinical Stage at Diagnosis
    • 4.4.16. Diagnosed Incident Cases of Larynx Cancer by Clinical Stage at Diagnosis
    • 4.4.17. Diagnosed Incident Cases of Thyroid Cancer by Clinical Stage at Diagnosis
    • 4.4.18. Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Histology Distribution
    • 4.4.19. Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers by Histology Distribution
    • 4.4.20. Diagnosed Incident Cases of Larynx Cancer by Histology Distribution
    • 4.4.21. Diagnosed Incident Cases of Thyroid Cancer by Histology Distribution
    • 4.4.22. Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer
    • 4.4.23. Five-Year Diagnosed Prevalent Cases of Larynx Cancer
    • 4.4.24. Five-Year Diagnosed Prevalent Cases of Thyroid Cancer
  • 4.5. Discussion
    • 4.5.1. Epidemiological Forecast Insight
    • 4.5.2. Limitations of the Analysis
    • 4.5.3. Strengths of the Analysis

5. Current Treatment Options

  • 5.1. Overview
  • 5.2. Product Profiles
    • 5.2.1. Erbitux (cetuximab)
    • 5.2.2. TS-1(tegafur + gimeracil + oteracil)
  • 5.3. Standard of Care Chemotherapy Review
    • 5.3.1. Cisplatin
    • 5.3.2. Docetaxel
    • 5.3.3. Fluorouracil (5-FU)
    • 5.3.4. Methotrexate

6. Unmet Needs Assessment and Opportunity Analysis

  • 6.1. Overview
  • 6.2. Unmet Needs Analysis
    • 6.2.1. Treatments for Recurrent and Metastatic Disease
    • 6.2.2. Treatments for Locally Advanced Head and Neck Cancers
    • 6.2.3. Treatments for HPV-negative Disease
    • 6.2.4. Management of Co-morbidities and Adverse Events Arising from Traditional Therapy
    • 6.2.5. Predictive Biomarkers to Guide and Improve the Current Treatments in Use
    • 6.2.6. Investment in Non-squamous Cell Carcinomas of the Head and Neck

7. R&D Strategies

  • 7.1. Overview
    • 7.1.1. Emergence of Immuno-Oncology Agents in the Late-Phase Pipeline
    • 7.1.2. Kinase Inhibitors in the Early Stage Pipeline
    • 7.1.3. Therapeutic HPV Vaccines for HPV-Positive Patients
  • 7.2. Clinical Trial Design
    • 7.2.1. Overall Patient Survival Most Important Outcome for Treatment
    • 7.2.2. Majority of New Drugs Targeting rmHNSCC
    • 7.2.3. Lack of Consistency in Comparator in the HNSCC Trials

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Drugs in Late-Stage Clinical Development
    • 8.2.1. Javlor (vinflunine)
    • 8.2.2. Gilotrif (afatinib)
    • 8.2.3. Multikine (leukocyte interleukin)
    • 8.2.4. Nimoral (nimorazole)
    • 8.2.5. Vectibix (panitumumab)
    • 8.2.6. Reolysin (pelareorep)
  • 8.3. Immune Checkpoint Inhibitors
    • 8.3.1. Overview
    • 8.3.2. Opdivo (nivolumab)
    • 8.3.3. Keytruda (pembrolizumab)
    • 8.3.4. Durvalumab (MEDI4736)
  • 8.4. Innovative Early-stage Approaches
    • 8.4.1. Therapeutic Cancer Vaccines
    • 8.4.2. Kinase Inhibitors for Prevention of Downstream Signaling
    • 8.4.3. Virus-based Therapies for the Treatment of Solid Tumors

9. Pipeline Valuation Analysis

  • 9.1. Clinical Benchmark of Key Pipeline Drugs
  • 9.2. Commercial Benchmark of Key Pipeline Drugs
  • 9.3. Competitive Assessment
  • 9.4. Top-Line Ten Year Forecast
    • 9.4.1. US
    • 9.4.2. 5EU
    • 9.4.3. Japan

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Diagnosed Head and Neck Cancer patients
    • 10.4.2. Percent Drug-treated Patients
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch and Patent Expiry Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Individual Drug Assumptions
    • 10.4.7. Generic Erosion
    • 10.4.8. Pricing of Pipeline Agents
  • 10.5. Physicians and Specialists Included in this Study
  • 10.6. About the Authors
    • 10.6.1. Author
    • 10.6.2. Reviewer
    • 10.6.3. Therapy Area Director
    • 10.6.4. Epidemiologist
    • 10.6.5. Reviewers
    • 10.6.6. Global Director of Therapy Analysis and Epidemiology
    • 10.6.7. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: ICD-10 Codes used to classify Head and Neck Cancers
  • Table 2: Head and Neck Cancer Locations and Their Clinically Defined Locations
  • Table 3: TNM Classification of Lip, Oral Cavity, and Oropharyngeal Cancers
  • Table 4: TNM Classification of the Larynx
  • Table 5: TNM Classification of the Hypopharynx
  • Table 6: TNM Classification of Nasal Cavity and Paranasal Sinus Cancers
  • Table 7: TNM Classification of Salivary Gland Cancers
  • Table 8: TNM Classification of Nasopharyngeal Cancers
  • Table 9: TNM Classification of Thyroid Gland Cancers
  • Table 10: Stage Grouping for Head and Neck Cancer (Excluding Nasopharyngeal and Thyroid Cancer)
  • Table 11: Stage Grouping for Nasopharyngeal Cancer
  • Table 12: Stage Grouping of Thyroid Gland Cancers
  • Table 13: Symptoms of Head and Neck Squamous Cell Carcinoma
  • Table 14: Risk Factors for HNC
  • Table 15: Trends in the Age-Adjusted Incidence of Lip, Oral Cavity, and Pharynx Cancer in the 7MM, All Ages, 1998-2007
  • Table 16: Trends in the Age-Adjusted Incidence of Larynx Cancer in the 7MM, All Ages, 1998-2007
  • Table 17: Trends in the Age-Adjusted Incidence of Thyroid Cancer in the 7MM, All Ages, 1998-2007
  • Table 18: Trends in the Five-Year Relative Survival (%) of HNC and Thyroid Cancer in the 7MM, Both Sexes, 1993-2007
  • Table 19: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer
  • Table 20: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Larynx Cancer
  • Table 21: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer
  • Table 22: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Thyroid Cancer
  • Table 23: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer
  • Table 24: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Larynx Cancer
  • Table 25: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Thyroid Cancer
  • Table 26: 7MM, Sources of Epidemiological Data Used for the Segmentation of Diagnosed Incident Cases of HNC (Excluding Nose, Sinuses, and Related Cancers) and Thyroid Cancer by Clinical Stage at Diagnosis
  • Table 27: 7MM, Sources of Epidemiological Data Used for the Segmentation of the Diagnosed Incident Cases HNC and Thyroid Cancer by Histology Distribution
  • Table 28: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, All Ages, N, 2014-2024
  • Table 29: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer, Both Sexes, All Ages, N, 2014-2024
  • Table 30: 7MM, Diagnosed Incident Cases of Larynx Cancer, Both Sexes, All Ages, N, 2014-2024
  • Table 31: 7MM, Diagnosed Incident Cases of HNC, Both Sexes, All Ages, N, 2014-2024
  • Table 32: 7MM, Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, All Ages, N, 2014-2024
  • Table 33: 7MM, Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, N (Row %), 2014
  • Table 34: 7MM, Age-Specific Diagnosed Incident Cases of Larynx Cancer, Both Sexes, N (Row %), 2014
  • Table 35: 7MM, Age-Specific Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, N (Row %), 2014
  • Table 36: 7MM, Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, N (Row %), 2014
  • Table 37: 7MM, Sex-Specific Diagnosed Incident Cases of Larynx Cancer, All Ages, N (Row %), 2014
  • Table 38: 7MM, Sex-Specific Diagnosed Incident Cases of Thyroid Cancer, All Ages, N (Row %), 2014
  • Table 39: 7MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, Both Sexes, N, 2014-2024
  • Table 40: 7MM, Five-Year Diagnosed Prevalent Cases of Larynx Cancer, All Ages, Both Sexes, N, 2014-2024
  • Table 41: 7MM, Five-Year Diagnosed Prevalent Cases of Thyroid Cancer, All Ages, Both Sexes, N, 2014-2024
  • Table 42: Leading Treatments for Head and Neck Cancers
  • Table 43: Product Profile - Erbitux
  • Table 44: Efficacy of Erbitux with Cisplatin and 5-FU in rmHNSCC Patients, in a Phase III, Randomized Open-Label Trial.
  • Table 45: Efficacy of Erbitux with Radiotherapy in Locally Advanced HNSCC in Phase III, Randomized Open-Label Trial.
  • Table 46: Safety of Erbitux with Cisplatin and 5-FU Chemotherapy in rmHNSCC
  • Table 47: Erbitux SWOT Analysis
  • Table 48: Global Sales Forecast ($m) for Erbtiux, 2014-2024
  • Table 49: Product Profile - TS-1
  • Table 50: Safety of TS-1 Monotherapy in Patients with rmHNSCC
  • Table 51: TS-1 SWOT Analysis
  • Table 52: Global Sales Forecast ($m) for TS-1, 2014-2024
  • Table 53: Overall Unmet Needs - Current Level of Attainment
  • Table 54: Phase III Pipeline Clinical Trial Design
  • Table 55: Head and Neck Squamous Cell Carcinoma - Late Stage Pipeline, 2015
  • Table 56: Product Profile - Javlor
  • Table 57: Efficacy of Javlor with Methotrexate in rmHNSCC from Single Arm, Phase I Dose Finding Trial (ASCO 2015)
  • Table 58: Safety of Javlor with Methotrexate in rmHNSCC from a Single Arm, Phase I Dose Finding Trial (ASCO 2015)
  • Table 59: Javlor SWOT Analysis
  • Table 60: Global Sales Forecast ($m) for Javlor, 2014-2024
  • Table 61: Product Profile - Gilotrif
  • Table 62: Efficacy of Gilotrif with Methotrexate in rmHNSCC
  • Table 63: Safety of Gilotrif with Methotrxate in rmHNSCC (NCT01345682)
  • Table 64: Gilotrif SWOT Analysis
  • Table 65: Global Sales Forecast ($m) for Gilotrif, 2014-2024
  • Table 66: Product Profile - Multikine (interleukin injection)
  • Table 67: Disclosed Components of Multikine - Major Cytokines and Other Cellular Products
  • Table 68: Multikine SWOT Analysis
  • Table 69: Global Sales Forecast ($m) for Multikine, 2014-2024
  • Table 70: Product Profile - Opdivo
  • Table 71: Safety of dacarbazine v. Opdivo in advanced melanoma (checkmate-066)
  • Table 72: Opdivo SWOT Analysis
  • Table 73: Global Sales Forecast ($m) for Opdivo, 2014-2024
  • Table 74: Product Profile - Keytruda
  • Table 75: Safety of Investigator's Chemotherapy versus Keytruda in Ipilimumab-Refractory Melanoma (KEYNOTE-002)
  • Table 76: Keytruda SWOT Analysis
  • Table 77: Global Sales Forecast ($m) for Keytruda, 2014-2024
  • Table 78: Product Profile - Durvalumab
  • Table 79: Safety of Durvalumab Single Agent in rmHNSCC from Single Arm, Phase I Dose Finding Trial (ASCO 2015)
  • Table 80: MEDI4736 SWOT Analysis
  • Table 81: Global Sales Forecast ($m) for durvalumab, 2014-2024
  • Table 82: Select early-stage pipeline products in HNSCC
  • Table 83: Clinical Benchmark of Key Pipeline Drugs - Locally advanced HNSCC
  • Table 84: Clinical Benchmark of Key Pipeline Drugs - rmHNSCC
  • Table 85: Commercial Benchmark of Key Pipeline Drugs
  • Table 86: Top Line Sales Forecasts ($million USD) for HNSCC, 2014-2024
  • Table 87: Key Events Impacting Sales for HNSCC
  • Table 88: HNSCC Market - Drivers and Barriers, 2014-2024
  • Table 89: Key Launch Dates, 2014-2024
  • Table 90: Key Patent Expiries, 2014-2024

List of Figures

  • Figure 1: Anatomical Sites of Head and Neck Cancers.
  • Figure 2: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, All Ages, N, 2014-2024
  • Figure 3: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer, Both Sexes, All Ages, N, 2014-2024
  • Figure 4: 7MM, Diagnosed Incident Cases of Larynx Cancer, Both Sexes, All Ages, N, 2014-2024
  • Figure 5: 7MM, Diagnosed Incident Cases of HNC, Both Sexes, All Ages, N, 2014-2024
  • Figure 6: 7MM, Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, All Ages, N, 2014-2024
  • Figure 7: 7MM, Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, N, 2014
  • Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of Larynx Cancer, Both Sexes, N, 2014
  • Figure 9: 7MM, Age-Specific Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, N, 2014
  • Figure 10: 7MM, Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, N, 2014
  • Figure 11: 7MM, Sex-Specific Diagnosed Incident Cases of Larynx Cancer, All Ages, N, 2014
  • Figure 12: 7MM, Sex-Specific Diagnosed Incident Cases of Thyroid Cancer, All Ages, N, 2014
  • Figure 13: 7MM, Age-Standardized Diagnosed Incidence Cases of Lip, Oral Cavity, and Pharynx Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014
  • Figure 14: 7MM, Age-Standardized Diagnosed Incidence Cases of Larynx Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014
  • Figure 15: 7MM, Age-Standardized Diagnosed Incidence Cases of Thyroid Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014
  • Figure 16: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014
  • Figure 17: 7MM, Diagnosed Incident Cases of Larynx Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014
  • Figure 18: 7MM, Diagnosed Incident Cases of Thyroid Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014
  • Figure 19: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014
  • Figure 20: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers by Histology Distribution, All Ages, Both Sexes, N, 2014
  • Figure 21: 7MM, Diagnosed Incident Cases of Larynx Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014
  • Figure 22: 7MM, Diagnosed Incident Cases of Thyroid Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014
  • Figure 23: 7MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, Both Sexes, N, 2014-2024
  • Figure 24: 7MM, Five-Year Diagnosed Prevalent Cases of Larynx Cancer, All Ages, Both Sexes, N, 2014-2024
  • Figure 25: 7MM, Five-Year Diagnosed Prevalent Cases of Thyroid Cancer, All Ages, Both Sexes, N, 2014-2024
  • Figure 26: Treatment Overview in HNSCC Patients
  • Figure 27: Treatment Overview in Nasopharyngeal Carcinoma Patients
  • Figure 28: Javlor's Development in HNSCC
  • Figure 29: Gilotrif's Development in HNSCC
  • Figure 30: Multikine's Development in HNSCC
  • Figure 31: Opdivo's Development in HNSCC
  • Figure 32: Keytruda's Development in HNSCC
  • Figure 33: Durvalumab's Development in HNSCC
  • Figure 34: Competitive Assessment of Marketed and Pipeline HNSCC Agents, 2014-2024
Back to Top